Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Merus N.V. Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference August 06, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update August 01, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC July 24, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC July 08, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer July 01, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting June 03, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting June 02, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Pricing of Upsized Public Offering of Common Shares May 29, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference May 29, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus N.V. Announces Proposed Public Offering of Common Shares May 28, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC May 28, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting May 23, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting May 23, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA May 13, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update May 08, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 06, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting April 24, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 April 08, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression March 05, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference March 04, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update February 28, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus to Participate in Upcoming Investor Conferences January 31, 2024 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023 December 02, 2023 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023 November 26, 2023 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update November 02, 2023 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus to Participate in Upcoming Investor Conferences November 01, 2023 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer October 23, 2023 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Business Update Conference Call October 15, 2023 From Merus N.V. Via GlobeNewswire Tickers MRUS Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023 October 06, 2023 From Merus N.V. Via GlobeNewswire Tickers MRUS Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.